[go: up one dir, main page]

TWI799923B - Use of thioimidazolidinone drugs in the treatment of covid-19 disease - Google Patents

Use of thioimidazolidinone drugs in the treatment of covid-19 disease Download PDF

Info

Publication number
TWI799923B
TWI799923B TW110127077A TW110127077A TWI799923B TW I799923 B TWI799923 B TW I799923B TW 110127077 A TW110127077 A TW 110127077A TW 110127077 A TW110127077 A TW 110127077A TW I799923 B TWI799923 B TW I799923B
Authority
TW
Taiwan
Prior art keywords
thioimidazolidinone
covid
drugs
disease
treatment
Prior art date
Application number
TW110127077A
Other languages
Chinese (zh)
Other versions
TW202227065A (en
Inventor
友之 童
馬連東
周千翔
嚴紅花
任志華
楊劍飛
Original Assignee
大陸商蘇州開拓藥業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商蘇州開拓藥業股份有限公司 filed Critical 大陸商蘇州開拓藥業股份有限公司
Publication of TW202227065A publication Critical patent/TW202227065A/en
Application granted granted Critical
Publication of TWI799923B publication Critical patent/TWI799923B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW110127077A 2020-12-31 2021-07-21 Use of thioimidazolidinone drugs in the treatment of covid-19 disease TWI799923B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202011640468 2020-12-31
CN202011640468.9 2020-12-31
CN202110657053.0 2021-06-11
CN202110657053.0A CN113143924B (en) 2020-12-31 2021-06-11 Application of thioimidazolidinone medicament in treating COVID-19 diseases

Publications (2)

Publication Number Publication Date
TW202227065A TW202227065A (en) 2022-07-16
TWI799923B true TWI799923B (en) 2023-04-21

Family

ID=76875845

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110127077A TWI799923B (en) 2020-12-31 2021-07-21 Use of thioimidazolidinone drugs in the treatment of covid-19 disease

Country Status (2)

Country Link
CN (1) CN113143924B (en)
TW (1) TWI799923B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022141328A1 (en) * 2020-12-31 2022-07-07 苏州开拓药业股份有限公司 Use of thioimidazolidinone drug in treating covid-19-related diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012119559A1 (en) * 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
CN106810542A (en) * 2015-11-30 2017-06-09 苏州开拓药业有限公司 A kind of crystal formation, salt form of thiocarbamoyl imidazole alkanone compound and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012119559A1 (en) * 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
CN106810542A (en) * 2015-11-30 2017-06-09 苏州开拓药业有限公司 A kind of crystal formation, salt form of thiocarbamoyl imidazole alkanone compound and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 , FA CADEGIANI, et al., "Proxalutamide (GT0918) reduces the rate of hospitalization and death in COVID-19 male patients: a randomized double-blinded placebo-controlled trial", Research Square, Preprint v1, Europe PMC. 29 Dec 2020, https://europepmc.org/article/PPR/PPR258803.
期刊 , S WU, et al., "Suppression of androgen receptor (AR)-ACE2/TMPRSS2 axis by AR antagonists may be therapeutically beneficial for male COVID-2019 patients", SSRN, SSRN, Posted: 18 Jun 2020, http://dx.doi.org/10.2139/ssrn.3580526.;期刊 , FA CADEGIANI, et al., "Proxalutamide (GT0918) reduces the rate of hospitalization and death in COVID-19 male patients: a randomized double-blinded placebo-controlled trial", Research Square, Preprint v1, Europe PMC. 29 Dec 2020, https://europepmc.org/article/PPR/PPR258803. *

Also Published As

Publication number Publication date
CN113143924B (en) 2023-04-14
CN113143924A (en) 2021-07-23
TW202227065A (en) 2022-07-16

Similar Documents

Publication Publication Date Title
IL314347A (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
IL289167A (en) 2h-indazole derivatives and their use in the treatment of disease
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
EP4215208A4 (en) Pharmaceutical combination and use thereof
EP3606570B8 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
EP3969125A4 (en) Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases
EP3915985A4 (en) Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease
EP4003355A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
EP4129283A4 (en) Pharmaceutical combination and use thereof
CA3264923A1 (en) Composition for use in the treatment of fabry disease
TWI799923B (en) Use of thioimidazolidinone drugs in the treatment of covid-19 disease
EP3644753A4 (en) Methods for maintaining and improving kidney function in patients with kidney disease and on standard of care therapy
EP4140480A4 (en) Drug combination and use thereof
EP4193995A4 (en) Use of btk inhibitors in the treatment of diseases
EP4234035A3 (en) A pharmaceutical combination for the treatment of a cancer
ITMI20021866A1 (en) PHARMACEUTICAL PREPARATION IN COLLOIDAL FORM USEFUL IN THE TREATMENT OF SKIN DISEASES.
EP4003987A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
EP4017496A4 (en) Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases
PL3937948T3 (en) Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases
EP3844168A4 (en) Combination drug formulations for treating patients with cardiovascular disease and associated conditions
EP4121035A4 (en) Use of bucillamine in the treatment of infectious diseases
EP4342492A4 (en) Pharmaceutical combination and use thereof
EP4129282A4 (en) Pharmaceutical combination and use thereof
EP4003997A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
HK40096009A (en) Use of medicament in treatment of tumor disease